The phenomenon of persistent natural killer (NK) cell lymphocytosis has recently been recognized as the provisional diagnostic entity 'chronic lymphoproliferative disorder of natural killer cells' (CLDNK) in the WHO (World Health Organization) classification of hematopoietic tumors. 1 CLDNK, which has also been known as the NK-type lymphoproliferative disorder of granular lymphocytes, is generally considered indolent, although there are few published cases. [2] [3] [4] The paucity of literature suggests that CLDNK is rare; however, disease recognition is problematic because NK cells lack a uniquely rearranged antigen receptor gene (such as T-cell receptor) to serve as a marker of clonal cellular expansion and to facilitate distinction from reactive processes. This feature renders flow cytometric immunophenotyping (FCIP) particularly important in diagnosing CLDNK, typically revealing CD16-positive and CD3-negative NK cells with diminished expression of CD56 and altered expression of a group of NK cell-associated receptors, which recognize major histocompatibility complex I and related antigens collectively referred to as NKRs. Abnormalities in NKRs recognized in CLDNKs include aberrancies in killer cell immunoglobulin-like receptor (KIR) and/or CD94 expression. 3, 5 Although these patterns of NKR expression have been shown to distinguish CLDNKs from normal controls, transient NK cell lymphocytosis with abnormal NKR expression has also been reported; therefore, repeat studies are generally recommended for the confirmation of a CLDNK diagnosis, although the utility of this practice has yet to be formally established. 3, 6, 7 Functionally and immunophenotypically distinct mature NK cell subsets, often referred to as CD56 bright and CD56 dim NK cells, based on their differential expression of this antigen, have recently been identified. CD56
bright NK cells are found primarily in secondary lymphoid tissues, are brightly NKp46 positive, dimly CD16 positive, have little or no KIR expression and have limited cytotoxic potential, functioning primarily through the elaboration of cytokines, such as interferon-g. In contrast, CD56 dim NK cells are found primarily in the peripheral blood, are dimly NKp46 positive, brightly CD16 positive, frequent KIR expressers and act primarily as cytotoxic effector cells. Although these NK cell subsets have disparate attributes, they are closely inter-related to CD56 dim NK cells derived from CD56 bright NK cells through activation and exposure to cytokines, such as interleukin-12 and interleukin-15. 8 In light of these advances in NK cell immunology, CLDNK cases from the Mayo Clinic (n ¼ 31) and the Medical College of Wisconsin (n ¼ 5) seen from 2000 to 2009 were reviewed with two primary aims. One was to establish the laboratory features required for the diagnosis of this uncommon entity, including determining the immunophenotypic stability of CLDNKs over time. The other aim was to determine whether the attributes of CLDNKs allowed cases to be ascribed to normal mature CD56 bright and/or CD56 dim NK cell subsets in a manner analogous to the subclassification of mature B-and T-cell lymphoproliferative disorders, and, if so, whether this subcategorization was clinically relevant.
In each CLDNK, the diagnosis was established through documented persistent lymphocytosis shown to be of NK cell lineage by FCIP. In this study, FCIP was performed using fluorochrome-conjugated antibodies to CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD56, CD57, CD94, CD161 and KIRs CD158a, CD158b and CD158e. Cells were considered antigen negative if 490% lacked antibody staining and antigen positive if X90% stained with the antibody of interest; a staining pattern intermediate between these was considered indicative of partial antigen expression (Figure 1a) . Antigen-positive cells with a fluorescent intensity midpoint below the second decade were considered dim, those with a fluorescent midpoint between the second and third decades were considered moderate and those with fluorescent midpoints near or beyond the third decade were considered moderately bright and bright, respectively. In normal peripheral blood, NK cell subsets are positive for each of the three tested KIRs, generating a polytypic pattern of KIR expression. 3, 6 By comparison, either the uniform lack of KIR expression (UN) or the uniform expression of a single KIR isoform (RES), with or without the expression of another KIR, are both considered abnormal and supportive of a diagnosis of CLDNK. In four study cases, there was a skewed KIR expression without the homocellular staining requisite for KIR restriction; this was considered to be of indeterminate Data review showed that the 36 CLDNK cases could be subcategorized into 3 distinct groups on the basis of CD56 expression (Table 1 and Figure 1a ). There was no statistical difference in the median NK cell counts between these groups (P ¼ 0.4). Anemia and neutropenia were more frequent in the CD56-partial and CD56-negative cases, with a statistically significant difference in the median hemoglobin and absolute neutrophil counts between the CD56-positive and CD56- Letters to the Editor negative groups (P ¼ 0.0019 and P ¼ 0.013, respectively). Thrombocytopenia was uncommon and minimal when present. Six CLDNK cases had mild splenomegaly (three CD56 negative, two CD56 positive and one CD56 partial positive); none had lymphadenopathy or rheumatoid arthritis. Detailed history was available in 22 cases; in each case, the indication for laboratory evaluation was lymphocytosis and/or unexplained cytopenias. Treatment was more frequent in CD56-negative CLDNKs, although this difference failed to reach statistical significance. Therapy usually consisted of low-dose prednisone, in combination with cyclophosphamide, methotrexate or cyclosporin. None of the untreated patients had progression of cytopenias, despite persistent or progressive lymphocytosis. One patient eventually underwent therapeutic splenectomy and allogeneic bone marrow transplantation 7 years after diagnosis. No disease-related deaths or transformation to more aggressive disorders were documented.
The circulating granular lymphocytes in CLDNKs were cytologically bland. Bone marrow biopsy was performed in 16 cases (3 CD56 positive, 3 CD56 partial and 10 CD56 negative); none had tumefactive lymphoid infiltrates, yet all had increased interstitial cytotoxic lymphocytes detected by immunohistochemistry. In 12 cases (2 CD56 positive, 3 CD56 partial and 7 CD56 negative), immunohistochemistry showed intrasinusoidal cytotoxic lymphocyte infiltrates characteristic of large granular lymphocyte disorders. 3 FCIP in all CLDNKs showed CD2-, CD7-and CD16-positive NK cells lacking CD3, CD4 and CD5. A single CD56-positive CLDNK had diminished CD2 expression; 16 cases had diminished CD7 expression (3 CD56 positive, 4 CD56 partial and 9 CD56 negative). In the remainder, expression of these antigens was unremarkable. Normal NK cells have a subset with dim CD8 expression; this CD8 expression pattern was seen in 20 CLDNKs. Of the remainder, 10 were CD8 negative and 6 were CD8 positive (5 dim and 1 bright). Similar to normal NK cells, CD57 was also partially expressed by 22 CLDNKs (59%); 7 were CD57 positive and 7 were CD57 negative. These CD8 and CD57 expression patterns were equally distributed among the CLDNK groups with the exception of the CD57-negative cases, 6 of which were CD56 negative.
All CLDNKs were CD16 positive; however, there were differences in antigen expression levels between groups ( Table 2) . Six of the eight (75%) CLDNK cases with either dim or moderate CD16 expression were CD56-positive. In contrast, 13 of the 20 (65%) CD16 bright cases were CD56-negative. CD94 expression also differed between CLDNK groups with bright, uniform expression most common in CD56-positive cases (Figure 1b) . In two brightly CD94-positive CLDNKs (one CD56 positive and one CD56 negative), additional FCIP studies documented the exclusive expression of the CD94/NKG2A heterodimeric receptor complex (data not shown). CD161 was assessed in 32 cases; the expression was more frequent in CD56-negative CLDNKs (9 cases positive) than in CD56-partial or CD56-positive cases (1 and 2 cases positive, respectively). However, CD161 expression was typically dim and partial, and therefore not particularly helpful in characterizing abnormal NK cells.
Either restricted KIR expression or complete lack of KIR antigens was observed in 32 of the 36 CLDNKs (Table 2 ). Significant differences were observed between groups with the most CD56-positive CLDNK lacking KIR and most CD56-negative CLDNK being KIR restricted (P ¼ 0.0093); the CD56 partial group had equal numbers of KIR-restricted and KIR-negative cases. The KIR-restricted CD56-positive CLDNKs expressed CD158b. The KIR-restricted CD56-partial and CD56-negative CLDNKs usually expressed CD158a (2 and 8 cases, respectively, Figure 1b) ; the remainder expressed CD158e, two with coexpression of CD158b (one partial and one homocellular). Partial CD158b was also seen in one CD158a KIR-restricted case. Indeterminate KIR expression was seen exclusively in cases with some level of CD56 expression. 
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Serial specimens were analyzed in 25 CLDNKs; the median interval between samplings was 306 days, and in 14 cases 42 specimens were analyzed. The NK cell count was stable or increased in 15 cases, 10 of which were untreated. The NK cell count decreased in 10 cases, 7 of which had documented treatment; the single known untreated case in this group had a modest initial NK count and the time between samplings was long (over 7 years). The NK cell immunophenotype, including NKR expression, remained virtually unchanged in 20 of 22 cases with complete FCIP data. In all, 6 of the 20 cases with immunophenotypically stable CLDNKs had received treatment, and in 5 of these 6 cases, the NK cell count decreased. Immunophenotypic stability was seen in all CLDNK groups and included two cases with indeterminate KIR expression.
The NK cell immunophenotype changed over time in two CLDNKs, neither of which had been treated. In one CD56-partial case the NK cells had indeterminate KIR at first analysis with overexpression of CD158e and coexpression of CD158b; at reanalysis after a period of almost 4 years, the NK cells in this case were CD158e KIR restricted, still with coexpression of CD158b by a minor subset. The other CLDNK with phenotypic drift was CD56-negative. In this instance, the disorder was immunophenotypically stable with homocellular CD158b and CD158e expression when analyzed at 1 year, but when analyzed after an interval of 2 years showed an indeterminate KIR pattern with skewed expression of these isoforms. In this case, the CD94 expression also changed from uniform to heterogenous; interestingly, these changes were associated with an increase, rather than a decrease, in the absolute NK cell count.
This study establishes CLDNK as a discrete entity, validating its recognition by the WHO. In keeping with most previous descriptions, CLDNK is clinically indolent and seems to rarely, if ever, have a fulminate aggressive course either at diagnosis or during extensive follow-up. Flow cytometry is essential for making the diagnosis; routine studies confirm NK cell lineage and can help show the presence of potentially abnormal cells. However, these studies alone are insufficient for fully characterizing indolent CLDNK, and therefore evaluation of the NKRs CD94 and KIR is critical. The abnormalities detected by comprehensive immunophenotyping are remarkably stable and provide a unique signature to confirm the diagnosis. This point is of primary importance in distinguishing CLDNK from transient NK cell expansions. Serial flow studies are sufficient for diagnosing CLDNK; however, bone marrow examination with immunohistochemistry can contribute, and may be warranted to also exclude other possible causes of cytopenias.
The findings of this study not only substantiate CLDNK as a bona fide entity but also allow for the recognition of disease subtypes directly related to normal mature NK cell compartments. CD56-positive CLDNKs have immunophenotypic features analogous to normal CD56 bright NK cells with relatively dim CD16 expression, bright expression of CD94/NKG2A heterodimer and frequent lack of KIR antigens. In contrast, CD56-negative CLDNKs have immunophenotypic attributes corresponding to normal CD56 dim NK cells, with brighter CD16, less frequent CD94 expression and frequent KIR restriction. These immunophenotypic differences are correlated with a greater severity of associated cytopenias in CD56-negative CLDNKs. CD56-partial CLDNKs bear a closer immunophenotypic resemblance to CD56-negative cases, and therefore to CD56 dim NK cells; cytopenias also appeared frequent in this group. However, not all of the immunophenotypic attributes of the CLDNK groups directly corresponded to those of the normal CD56 bright and CD56 dim NK cell subsets; CD8 and CD57 are more often expressed by cytotoxic effector NK cells, yet CD8 expression did not differ between CLDNK groups and lack of CD57 was preferentially seen in CD56-negative cases. Moreover, these findings do not account for the preferential expression of the KIR CD158a by the CD56-partial and CD56-negative cases. The lack of cytopenias or other clinical findings in most CD56-positive CLDNKs raises the question of whether these cases should be included in this diagnostic category. Similar to other CLDNKs, however, these cases are characterized by persistent immunophenotypically stable NK cell expansion and in some cases require treatment. Finally, these studies do not address the broader question of whether CLDNK represents an autonomous hematolymphoid proliferation or an abnormal expansion of a functional cell compartment driven by some as yet unidentified stimulus. Regardless, the accurate diagnosis and immunophenotypic categorization of CLDNK can provide valuable information to clinicians regarding the nature of a persistent lymphocytosis, the cause of unexplained cytopenias and potentially the need for therapy.
